Show simple item record

dc.contributor.authorKieran, Jennifer Ann
dc.contributor.authorNorris, Suzanne
dc.contributor.authorO'Leary, Aisling
dc.contributor.authorWalsh, Cathal
dc.contributor.authorMerriman, Raphael
dc.contributor.authorHoulihan, D
dc.contributor.authorMcCormick, P Aiden
dc.contributor.authorMcKiernan, Susan
dc.contributor.authorBergin, Colm
dc.contributor.authorBarry, Michael
dc.date.accessioned2017-03-07T10:06:49Z
dc.date.available2017-03-07T10:06:49Z
dc.date.issued2015-10-26
dc.identifier.citationHepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. 2015, 15:471 BMC Infect. Dis.en
dc.identifier.issn1471-2334
dc.identifier.pmid26503519
dc.identifier.doi10.1186/s12879-015-1208-1
dc.identifier.urihttp://hdl.handle.net/10147/621143
dc.description.abstractRecent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs.
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to BMC infectious diseasesen
dc.subjectHEPATITIS Cen
dc.subjectHEALTH ECONOMICSen
dc.subject.meshAdult
dc.subject.meshAmbulatory Care
dc.subject.meshAntiviral Agents
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshCost-Benefit Analysis
dc.subject.meshCosts and Cost Analysis
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshHepatitis C
dc.subject.meshHepatitis C, Chronic
dc.subject.meshHumans
dc.subject.meshIreland
dc.subject.meshLiver Cirrhosis
dc.subject.meshLiver Neoplasms
dc.subject.meshLiver Transplantation
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.titleHepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.en
dc.typeArticleen
dc.identifier.journalBMC infectious diseasesen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-27T19:53:50Z
html.description.abstractRecent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs.


Files in this item

Thumbnail
Name:
RealWorldCostsUntreatedChronic ...
Size:
568.8Kb
Format:
PDF
Description:
OA Article

This item appears in the following Collection(s)

Show simple item record